US EditionPublished • loading... • Updated
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
- Virax Biolabs Group Limited announced a private placement of 12,500,000 ordinary shares at a purchase price of $0.40 per share.
- The gross proceeds from the private placement are expected to be $5 million before deducting fees and expenses.
- H.C. Wainwright & Co. is the exclusive placement agent for this offering.
- The private placement is anticipated to close on or about December 4, 2025, pending customary closing conditions.
Insights by Ground AI
48 Articles
48 Articles
The Berkshire Eagle+47 Reposted by 47 other sources
Virax Biolabs Group Limited Announces $5 Million Private Placement
LONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the…
Coverage Details
Total News Sources48
Leaning Left3Leaning Right6Center13Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
14%
C 59%
R 27%
Factuality
To view factuality data please Upgrade to Premium
